IMVIF.US IMV Inc.

Healthcare Biotechnology USA Stocks
0.0020 USD
Close of Nov 15, 2026
Market cap
USD 23.4K
P/E
-
P/B
8.87x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is IMVIF.US undervalued?

Graham number

The Graham number of IMV Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IMV Inc. fundamental analysis

No fundamental analysis for IMV Inc. yet.

IMV Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IMV Inc.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in…

Full company profile